Contraception
Volume 81, Issue 1 , Pages 57-61 , January 2010

Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use

  • Inka Wiegratz

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt, Germany
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, J.W. Goethe University, D-60590 Frankfurt am Main, Germany. Tel.: +49 69 63015708.
    • ,
  • Skadi Stahlberg

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt, Germany
    • ,
  • Torsten Manthey

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt, Germany
    • ,
  • Nicole Sänger

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt, Germany
    • ,
  • Katrin Mittmann

      Affiliations

    • Jenapharm GmbH & Co KG, D-07745 Jena, Germany
    • ,
  • Ernesta Palombo-Kinne

      Affiliations

    • Jenapharm GmbH & Co KG, D-07745 Jena, Germany
    • ,
  • Uwe Mellinger

      Affiliations

    • Jenapharm GmbH & Co KG, D-07745 Jena, Germany
    • ,
  • Evelyn Lange

      Affiliations

    • Jenapharm GmbH & Co KG, D-07745 Jena, Germany
    • ,
  • Herbert Kuhl

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt, Germany

Received 4 May 2009 ,Revised 30 July 2009 ,Accepted 30 July 2009.

References 

  1. Petitti DB, Sidney S, Quesenberry CP. Oral contraceptive use and myocardial infarction. Contraception. 1998;57:143–155
  2. Khader YS, Rice J, John L, Abueita O. Oral contraceptive use and the risk of myocardial infarction: a meta-analysis. Contraception. 2003;68:11–17
  3. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90:3863–3870
  4. Tanis BC, van den Bosch MAAJ, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345:1787–1793
  5. Margolis KL, Adami HO, Luo J, Ye W, Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril. 2007;88:310–316
  6. Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Contraception. 1998;57:189–201
  7. Godsland IF. Biology: risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas. 2004;47:299–303
  8. Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects?. Trends Endocrinol Metab. 2004;15:277–285
  9. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs. 2004;64:2447–2462
  10. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
  11. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception. 2004;69:37–42
  12. Kuhl H, Wiegratz I. Metabolic and clinical effects of progestogens. Eur J Contracept Reprod Health Care. 2006;11:153–161
  13. Wiegratz I, Lee JH, Kutschera E, Bauer HH, et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception. 2002;65:223–229
  14. März W, Jung-Hoffmann C, Heidt F, Gross W, Kuhl H. Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel. Contraception. 1990;41:245–258
  15. Rubeck Petersen K, Skouby SO, Gronholt Pedersen R. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol. 1991;78:666–672
  16. Song S, Chen JK, Yang PJ, et al. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception. 1992;45:523–532
  17. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin–aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821
  18. Kuhl H, Jung-Hoffmann C, Fitzner M, März W, Gross W. Short- and long-term effects on lipid metabolism of oral contraceptives containing 30 μg ethinylestradiol and 150 μg desogestrel or 3-keto-desogestrel. Horm Res. 1995;44:121–125
  19. Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception. 1998;58:83–91
  20. van der Mooren MJ, Klipping C, van Aken B, Helmerhorst EM, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 μg/ethinylestradiol 15 μg and desogestrel 150 μg/ethinylestradiol 20 μg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999;4(Suppl 2):27–35
  21. Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception. 2001;63:1–11
  22. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005;71:409–416
  23. Wiegratz I, Hertwig B, Jung-Hoffmann C, Kuhl H. Inhibition of low-density lipoprotein oxidation in vitro and ex vivo by several estrogens and oral contraceptives. Gynecol Endocrinol. 1996;10(Suppl 2):149–152
  24. Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception. 1994;50:153–165
  25. Bonassi Machado R, Fabrini P, Machado Cruz A, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg). Contraception. 2004;70:365–370

☆ The study was financially supported by Jenapharm GmbH & Co KG (Jena, Germany).

PII: S0010-7824(09)00356-4

doi: 10.1016/j.contraception.2009.07.011

Contraception
Volume 81, Issue 1 , Pages 57-61 , January 2010

Article Tools

* Image Usage & Resolution